Tuesday, May 22, 2018 | ICH Day

8:30-10:00	2nd Floor, Hall 2-I | **ICH Plenary Session**				
10:00-10:30	Tea Break				
10:30-17:00 *(Lunch & Tea Break in Between)*	2nd Floor 201AB **E2 & M1** Pharmacovigilance and MedDRA	2nd Floor 201CD **E6(R2)** GCP	2nd Floor, Hall 2-II **E9 (R1)** Estimands and Sensitivity Analysis in Clinical Trials 2nd Floor, Hall 2-II **E17** General Principles for Planing and Design of Multi-Regional Clinical Trials	2nd Floor, 203AB **E14** The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs	2nd Floor, 203CD **M4 & M8** Requirements and Significance of eCTD Implementation

Wednesday, May 23, 2018

14:00-16:30	2nd Floor, Hall 1 | **Opening Plenary**
16:30-18:00	1st Floor, Exhibition Area | **Welcome Reception**
18:00-20:00	2nd Floor, Hall 1 | **DIA China 10th Anniversary & Award Ceremony** (Invitation Only)

Thursday, May 24, 2018

	Reguatory Science	Innovative Breakthrough in Therapy	Clinical Development	Quantitative Science		Biologics and Biosimilars
8:30-10:00	0101 2nd Floor, Hall 2-C Real-world Evidence Defined and Re-defined: Regulatory and Practical Considerations for Drug Development Part 1	0301 2nd Floor, Hall 2-A MDR Bacteria - What's New in Antibiotic Development Part 1: Regulatory Issues	0401 2nd Floor, Hall 3 Hospital Presidents Forum - Part 1	0501-1 2nd Floor, 203AB Informetric Technology to Enhance the Quality and Integrity of Clinical Data	0501-2 2nd Floor, 203CD Statistics Topics in Rare Disease Drug Development	0601 3rd Floor, 307 Recent Trends in the Regulation of Biosimilar
10:00-10:30	Tea Break					
10:30-12:00	0102 2nd Floor, Hall 2-C Real-world Evidence Defined and Re-defined: Regulatory and Practical Considerations for Drug Development Part 2	0302 2nd Floor, Hall 2-A MDR Bacteria - What's New in Antibiotic Development Part 2: Clinical Development	0402 2nd Floor, Hall 3 Hospital Presidents Forum - Part 2	0502-1 2nd Floor, 203AB Information Technology to Enhance the Efficiency and Quality of Drug Development	0502-2 2nd Floor, 203CD Innovative Statistics Methods in Dose Finding - Method, Status and Implementation	0602 3rd Floor, 307 Clinical Trial Design of Biologics
12:00-13:30	Lunch					
13:30-17:00	0203 & 0204 | 2nd Floor, Hall 1 | **China NDA Townhall**					

Friday, May 25, 2018

8:30-10:00	0105 2nd Floor, Hall 3 Foreign Data to Support Registration E5, E17 - Part 1	0305-1 2nd Floor, Hall 2-A Checkpoint Inhibitors: Monotherapy vs. Combination Therapy	0305-2 2nd Floor, Hall 2-B Unmet Needs in Current Therapies for Liver Disease	0405 2nd Floor, Hall 2-C English Only How Collaboration is Driving Innovation in Research & Development	0505-1 2nd Floor, 203AB Quality Specification of Clinical Data in Clinical Trials	0505-2 2nd Floor, 203CD Bridge the Gap Between RWE vs. RCT Part 1	0605 3rd Floor, 307 Pharmaco-metrics in Early Stage of Clinical Development
10:00-10:30	Tea Break						
10:30-12:00	0106 2nd Floor, Hall 3 Foreign Data to Support Registration E5, E17 - Part 2	0306-1 2nd Floor, Hall 2-A New Approach for Oncotherapy Development	0306-2 2nd Floor, Hall 2-B Clinical Endpoints for Viral Hepatitis Therapy: Perspectives from Regulatory Professionals	0406 2nd Floor, Hall 2-C Clinical Trial AE Reporting—from Collection, to Processing, Analysis and Summary, to Authority Review	0506-1 2nd Floor, 203AB Cross Functional Cooperation to Ensure Data Quality	0506-2 2nd Floor, 203CD Bridge the Gap Between RWE vs. RCT Part 2	0606 3rd Floor, 307 Biosimilar Assessment based on Analytical and Pharmaco-kinetics Studies
12:00-13:30	Lunch						
13:30-15:00	0107 2nd Floor, Hall 3 Priority Review and Conditional Approval	0307-1 2nd Floor, Hall 2-A Development of Innovative CAR-T Therapy	0307-2 2nd Floor, Hall 2-B Immunotherapy for HBV Functional Cure	0407 2nd Floor, Hall 2-C New Technology to Support Clinical Trial Activity	0507-1 2nd Floor, 203AB Clinical Data Management for Domestic Pharmaceutical Globalization	0507-2 2nd Floor, 203CD Statistical Topics in Drug Development of Immune-Oncology	0607 3rd Floor, 307 Innovative Biologics Process Development
15:00-15:30	Tea Break						
15:30-17:00	0108 2nd Floor, Hall 3 MAH Pilot Program in China, Experience and Reflection	0308-1 2nd Floor, Hall 2-A Next-generation Sequencing and Predictive Biomarkers in Cancer Therapies	0308-2 2nd Floor, Hall 2-B Breakthrough of Therapeutic Development in Liver Disease	0408 2nd Floor, Hall 2-C The Critical Strategy and Practice of Efficient Collaborative Clinical Operation in New Environment	0508-1 2nd Floor, 203AB Clinical Data Management in Oncological Trials		0608 3rd Floor, 307 Development of Cell Therapy and Regulatory Considerations

The 10th DIA China Annual Meeting

May 22 ICH Day | May 23-25 Conference, Exhibition and Posters
Beijing International Convention Center

Weibo

Wechat Subscription

DIA China Home Page

DIAmond **Sessions**
Live Steam
Live Steam Member Only
Simultaneous Translation

Thursday, May 24, 2018

Generic Drug, CMC & GMP Inspection	Medical Writing & Medical Affairs	Safety	Patient Engagement	Artifical Intelligence	Medical Devices	Hot Topics and Late Breakers	White Paper Showcase	
0701 2nd Floor, 201CD English Only GMP - FDA Special Session	0801 3rd Floor, 305AB Introduction and Experience Sharing for Clinical Submission Documents after the CFDA Joins the ICH	0901 3rd Floor, 305CD How to Improve Safety Reporting in Clinical Trial	-	1101 2nd Floor, 201AB Artificial Intelligence and Big Data in the Field of Medical Reform and Drug Development	1201 3rd Floor, 308 New Medical Device Regulations on Market Permission Set to Accelerate Innovation Industry - Part 1	-	1401-1 3rd Floor, 302 The Evolved Solution to the Constant Problem: Patient Recruitment and Patient Outcome	1401-2 3rd Floor, 303 RBM of Risk Management in Clinical Trials
Tea Break								
0702 2nd Floor, 201CD ICH M9 Guideline: Biopharma-ceutics Classification System (BCS) - Based Biowaivers	0802 3rd Floor, 305AB Toward a Collaborative and Efficient Clinical Document Preparation	0902 3rd Floor, 305CD Post-Marketing Risk Management	-	1102 2nd Floor, 201AB AI in Clinical Trial Application – Challenge and Solution Part 1	1202 3rd Floor, 308 New Medical Device Regulations on Market Permission Set to Accelerate Innovation Industry - Part 2	1302 3rd Floor, 305 E Clinical QMS Evolution and Effectiveness Check	1402-1 3rd Floor, 302 Innovative Drug Clinical Research & Development in the New Era	1402-2 3rd Floor, 303 Covance White Paper Showcase Session: Driving Global Innovation with an Integrated Drug Development Strategy
Lunch								
0203 & 0204 | 2nd Floor, Hall 1 | **China NDA Townhall**								

Friday, May 25, 2018

0705 2nd Floor, 201CD Quality and Innovation – Key to Success in Global Generic Drug Market Part 1	0805 3rd Floor, 305AB Multi-Channels Medical Communication	0905 3rd Floor, 305CD Labeling Across Product Life Cycle	1005 3rd Floor, 308 Patient Initiatives Program - the Global Perspectives	1105 2nd Floor, 201AB AI in Clinical Trial Application – Challenge and Solution Part 2		1305 3rd Floor, 305E DIA - BayHelix Joint Investment Forum	1405-1 3rd Floor, 302 How can 3AUDIT Help Drug Safety Management	1405-2 3rd Floor, 303 Strategies and Technologies in Early Clinical Drug Development to Maximize Program Outcomes
Tea Break								
0706 2nd Floor, 201CD Quality and Innovation – Key to Success in Global Generic Drug Market Part 2	0806 3rd Floor, 305AB Phase IV Study and Management of Investigator Initiated Trial	0906 3rd Floor, 305CD PV Information System	1006 3rd Floor, 308 China's Progress in Rare Diseases	1106 2nd Floor, 201AB Big Data & AI in Clinical Trial Application – Challenge and Solution Part 3 Panel Discussion		-	1406-1 3rd Floor, 302 Network breaking-The Way to Explore the "New Service" in Clinical Research	1406-2 3rd Floor, 303 Trending of innovative medicine development China vs. Global
Lunch						3rd Floor, 305E The Talent Development in Responding to the Booming Life Science Future	1407-1 3rd Floor, 302 Practice and Application of Medical Language Intelligence Technology	1407-2 3rd Floor, 303 The NEXT Generation of Clinical Development
	0807 3rd Floor, 305AB Life Cycle Medical Strategy	0907 3rd Floor, 305CD Cardiovascular Safety of Anticancer Drugs in Development	1007 3rd Floor, 308 Rare Diseases Forum Part 1: Cases Sharing			1307 3rd Floor, 305E Clinical Operation Personnel Career Development Forum		
Tea Break								
	0808 3rd Floor, 305AB Career Development of Medical Affairs Personnel	0908 3rd Floor, 305CD ICH E2 Guideline Update	1008 3rd Floor, 308 Rare Diseases Forum Part 2: Panel Discussion			1308 3rd Floor, 305E Regulatory Agency vs. Regulated Industry - Keys to A Successful Regulatory Career Path		